Specifically, elevated CSF α-synuclein with lower NfL levels would favor a diagnosis of PD, while elevated levels of both biomarkers would be more indicative of DLB or MSA, effectively excluding synucleinopathies when not present [109,116]. The gene discussed is NEFL; the disease is multiple system atrophy.